Finally, a cross-disease study was performed to monitor CXCL12 levels in sALS, multiple sclerosis (MS), Alzheimer’s disease (AD), frontotemporal dementia behavioral variant (FTD), and type III spinal muscular atrophy (SMA). This evidence concerns the gene CXCL12 and frontotemporal dementia.